ScienceDaily (Nov. 14, 2008) — Patients treated for locally advanced non-small cell lung cancer who receive chemotherapy and proton beam therapy have fewer instances of bone marrow toxicity than patients who receive the standard treatment of intensity-modulated radiation (IMRT) and concurrent chemotherapy, according to researchers from The University of Texas M. D. Anderson Cancer Center.
Monday, November 17, 2008
Novel Four-drug Combination Proves Safe For Lung Cancer Treatment
ScienceDaily (Nov. 14, 2008) — The four drug-combination of carboplatin and paclitaxel, with the targeted therapies bevacizumab (Avastin) and cetuximab (Erbitux), is safe and may improve survival for patients with advanced lung cancer, according to a cooperative group study led by The University of Texas M. D. Anderson Cancer Center.
Gender Is Key Factor In Determining Overall Survival Of Lung Cancer Patients
ScienceDaily (Nov. 14, 2008) — Even though some combinations of gender, race and/or marital status can factor into the overall survival of nonoperative non-small cell lung cancer patients, gender is the most significant factor impacting overall survival, according to a study presented at the 2008 Chicago Multidisciplinary Symposium in Thoracic Oncology, sponsored by ASTRO, ASCO, IASLC and the University of Chicago.
Thursday, November 13, 2008
LCA News:LCA and AstraZeneca Release Stigma Survey Results
SURVEY SHOWS LUNG CANCER PATIENTS BLAMED FOR THEIR DIAGNOSIS
As public support decreases, so do research dollars and patient hope
As public support decreases, so do research dollars and patient hope
Washington, DC, November 12, 2008 – Survey results released today show that the general population blames lung cancer patients for their diagnosis, confirming the stigma that patients reportedly feel. Findings also demonstrate a lack of public support for patients and a need for greater research for the number one cancer killer. Conducted by Lung Cancer Alliance and AstraZeneca, LP (NYSE: AZN), the national survey assessed the views of lung cancer patients, oncologists and the general public on lung cancer, support for lung cancer organizations, research funding for the disease, and availability of appropriate treatment options.
“This survey reinforces what the lung cancer community has felt for decades – public perception of this disease is overwhelmingly negative,” said Laurie Fenton Ambrose, President and CEO of Lung Cancer Alliance. “We’ve got to do more to overcome this pervasive stigma and focus attention where it should be -- on research for early detection and treatment for lung cancer.”
“This survey reinforces what the lung cancer community has felt for decades – public perception of this disease is overwhelmingly negative,” said Laurie Fenton Ambrose, President and CEO of Lung Cancer Alliance. “We’ve got to do more to overcome this pervasive stigma and focus attention where it should be -- on research for early detection and treatment for lung cancer.”
ABC of San Francisco reports: Survivor urges early lung cancer screening
November 12, 2008By Cheryl Jennings
REDWOOD CITY, CA (KGO) -- You may be surprised to know that lung cancer is the number one cancer killer in the United States, according to the National Cancer Institute. People do not like to talk about it because there is a stigma associated with smoking, but lung cancer is also striking down more non-smokers. We talked to a lung cancer survivor whose family is using every tool available to save lives.
http://abclocal.go.com/kgo/story?section=news/health&id=6502358
Subscribe to:
Posts (Atom)
Kick Butts Today!
